Close

Diabeloop and EOFlow Partner to Offer a Wearable AID With a Smartphone App

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

WHO Supplies Medical Equipment for Post-Marburg...

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK...

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences...

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized...

The Human Medicines Regulations 2025, which came into force...

EOFlow and Diabeloop announced that they have partnered to bring an AID system, connecting EOFlow’s wearable insulin pump EOPatch, a third-party continuous glucose monitoring (CGM) device and Diabeloop’s automated insulin delivery (AID) algorithm integrated in the Diabeloop’s smartphone app, currently in development. The Companies also plan to integrate the EOPatch insulin pump into the DBLG1 System of Diabeloop, integrating the algorithm in a dedicated handset.

According to the Companies, the AID is developed by incorporating the algorithm ‘DBLG1’, the wearable insulin pump ‘EOPatch’ and a third-party CGM, which all have already received CE markings, and could be proposed to patients soon after the development has been completed. Commercial launch in Europe is therefore expected from the end of 2023.

Diabeloop, following its interoperable strategy, is currently collaborating or in discussion with several device manufacturers and is developing its smartphone app. Partnering with EOFlow, which has a disposable, tubeless insulin pump solution and experience with app controlling, would feed a great need of patients for performing wearable solutions.

EOFlow officially launched its tubeless, wearable, and disposable insulin pump ‘EOPatch’ in Korea and in Europe (by its European partner, A. Menarini Diagnostics with its GlucoMen Day brand) with its smartphone application ‘Narsha’ registered on Google Play Store and Apple AppStore. Narsha is the first app in the world for smartphones that allows users to monitor and control the wearable insulin pump. With the convenience and discretion it offers, Narsha is attracting a lot of new and potential pump users in Europe.

 

Latest stories

Related stories

WHO Supplies Medical Equipment for Post-Marburg Virus Heal

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back